OPRM1 DNA methylation is linked to lower opioid use disorder cases in women, with patients with lower methylation and the mutant G-allele requiring less opioids. COMT DNA methylation levels negatively affect pain relief quality of life and adverse events like constipation, insomnia, and nervousness. This evidence concerns the gene OPRM1 and opioid use disorder.